Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05386524 | Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC | unknown | Phase 2 | 41 | Fudan UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02983071 | G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | unknown | Phase 1 / Phase 2 | 102 | G1 Therapeutics, Inc.INDUSTRY | 4 | Feb 15, 2023 | clinicaltrials |
| NCT05726175 | Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer | unknown | Phase 2 | 20 | West China HospitalOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05453825 | A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | unknown | Phase 2 | 180 | OncXerna Theraputics, Inc.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT04248998 | Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer(BREAKFAST) | unknown | Phase 2 | 30 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT04582968 | Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases | unknown | Phase 1 / Phase 2 | 39 | Fudan UniversityOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT05681728 | A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer | unknown | Phase 2 | 26 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT04001621 | Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer | unknown | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT05619016 | [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors | unknown | Phase 2 | 72 | Karolinska University HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05622227 | 68Ga PET/CT Imaging in Breast Cancer Patients | unknown | Phase 1 / Phase 2 | 50 | Peking Union Medical College HospitalOTHER | 1 | Nov 18, 2022 | clinicaltrials |
| NCT05411380 | Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor. | unknown | Phase 2 | 73 | wang shusenOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT05103644 | Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients" | unknown | Phase 2 / Phase 3 | 60 | Beni-Suef UniversityOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT03907800 | Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer(NeoPATH) | unknown | Phase 2 | 100 | Ruijin HospitalOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05595109 | Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients | unknown | Phase 2 / Phase 3 | 56 | Tanta UniversityOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT04192331 | Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast Cancer | unknown | Phase 2 | 97 | Peking University Cancer Hospital & InstituteOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT05577923 | Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower) | unknown | Phase 2 | 126 | Fudan UniversityOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT05566457 | HGWD Improve the Paclitaxel-related Neurotoxicity in Patients With BC | unknown | Phase 2 | 92 | Chinese Academy of Medical SciencesOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05085626 | Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05560334 | A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05518292 | Comparison of Analgesic Efficacy of Ultrasound Guided Rhomboid Intercostal Block Versus Serratus Anterior Plane Block for Mastectomy Surgery | unknown | Phase 2 / Phase 3 | 60 | Mansoura UniversityOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT05546255 | Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer | unknown | Phase 2 | 40 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT05357417 | Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases | unknown | Phase 2 | 100 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 16, 2022 | clinicaltrials |
| NCT05186545 | An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer | unknown | Phase 2 | 63 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Sep 2, 2022 | clinicaltrials |
| NCT04398446 | Effect of Hemp-CBD on Patients With CIPN(Coala-T-CBD) | unknown | Phase 2 | 56 | Main Line HealthOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05512416 | Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer | unknown | Phase 2 | 35 | The Affiliated Hospital of Qingdao UniversityOTHER | 0 | Aug 23, 2022 | clinicaltrials |
| NCT05498311 | Breast Cancer With Intraoperative Radiotherapy Followed by Hypofractionated External Beam Radiotherapy(IORT_BREAST) | unknown | Phase 2 | 89 | Institut Català d'OncologiaOTHER | 1 | Aug 15, 2022 | clinicaltrials |
| NCT03805399 | FUSCC Refractory TNBC Umbrella (FUTURE)(FUTURE) | unknown | Phase 1 / Phase 2 | 140 | Fudan UniversityOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT05007444 | Safety and Efficacy Evaluation of the P2Et Extract in Patients With Breast Cancer | unknown | Phase 2 | 58 | Hospital Universitario San IgnacioOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05491694 | To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer(HIFU) | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 8, 2022 | clinicaltrials |
| NCT04355858 | Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer(MULAN) | unknown | Phase 2 | 319 | Fudan UniversityOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT04297267 | A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant Chemotherapy(nonpCR GP) | unknown | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT05469750 | Dalpiciclib Plus Letrozole and Capecitabine | unknown | Phase 2 | 48 | Fujian Medical University Union HospitalOTHER | 0 | Jul 22, 2022 | clinicaltrials |
| NCT05461690 | Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency | unknown | Phase 2 | 50 | Zhejiang Cancer HospitalOTHER | 0 | Jul 18, 2022 | clinicaltrials |
| NCT00496795 | Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer(DDP) | unknown | Phase 2 | 100 | University of BergenOTHER | 1 | Jun 29, 2022 | clinicaltrials |
| NCT05429294 | Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038 | unknown | Phase 2 | 209 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT04881929 | Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer | unknown | Phase 2 | 30 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05400993 | Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC | unknown | Phase 2 | 59 | Shengjing HospitalOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT05133674 | Therapeutic Dose Monitoring (TDM) of Tamoxifen | unknown | Phase 2 | 40 | Karolinska University HospitalOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT03913234 | Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients | unknown | Phase 1 / Phase 2 | 95 | Yonsei UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT04334330 | Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China | unknown | Phase 2 | 34 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT04722718 | Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer | unknown | Phase 2 | 34 | Jiuda ZhaoOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT04605575 | Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer | unknown | Phase 2 | 208 | Sun Yat-sen UniversityOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT05346107 | PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer | unknown | Phase 2 | 100 | Xijing HospitalOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT05346328 | HER2-positive Breast Cancer Project Initiated by Investigators | unknown | Phase 2 | 48 | Fudan UniversityOTHER | 0 | Apr 26, 2022 | clinicaltrials |
| NCT02341911 | Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)(TNBC) | unknown | Phase 2 | 150 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT02607215 | Platinum Rechallenge in Patients With Platinum-sensitive mTNBC | unknown | Phase 2 | 84 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Feb 16, 2023source: clinicaltrials